Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 5/20 | 0.76 |
| ▸ | NR4A2 | P43354 | 5/20 | 0.73 |
| ▸ | RXRA | P19793 | 5/20 | 0.73 |
| ▸ | RXRB | P28702 | 5/20 | 0.73 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.70 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.66 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.66 |
| ▸ | NPC1 | O15118 | 1/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.65 |
| ▸ | RAB9A | P51151 | 1/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.65 |
| ▸ | RXRG | P48443 | 1/20 | 0.64 |
| ▸ | PPARA | Q07869 | 1/20 | 0.64 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19951231 | 1.00 | MAOB (0.76) | MAOBNR4A2RXRARXRBMRGPRX4 | |
| SCHEMBL8134318 | 0.87 | NR4A2 (0.85) | NR4A2RXRARXRBNR4A1NR4A3 | |
| SCHEMBL30576796 | 0.86 | MAOB (1.00) | MAOBNR4A2MRGPRX4 | |
| SCHEMBL18002926 | 0.86 | MAOB (1.00) | MAOBNR4A2RXRARXRBSMN1; SMN2 | |
| SCHEMBL9813418 | 0.84 | RXRA (1.00) | MAOBNR4A2RXRARXRBNR4A1 | |
| SCHEMBL22721344 | 0.84 | MRGPRX4 (0.70) | NR4A2RXRARXRBMRGPRX4NR4A1 | |
| SCHEMBL8459965 | 0.84 | RXRA (1.00) | MAOBNR4A2RXRARXRBNR4A1 | |
| SCHEMBL23605980 | 0.84 | PPARA (0.75) | MAOBMRGPRX4SMN1; SMN2PPARA | |
| SCHEMBL21991486 | 0.84 | MAOB (0.67) | MAOBMRGPRX4PPARA | |
| SCHEMBL3498978 | 0.84 | MAOB (0.67) | MAOBRXRARXRBMRGPRX4RXRG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8680150-B2 | Small molecule hematopoietic growth factor mimetic compounds that activate hematopoietic growth factor receptors | LIGAND PHARMACEUTICALS, INC. (US) | 2014-03-25 | — | — | US | disclosed |
| US-20110003851-A1 | SMALL MOLECULE HEMATOPOIETIC GROWTH FACTOR MIMETIC COMPOUNDS THAT ACTIVATE HEMATOPOIETIC GROWTH FACTOR RECEPTORS | LIGAND PHARMACEUTICALS, INC. (US) | 2011-01-06 | — | — | US | disclosed |
| US-20040077654-A1 | Aryl piperidine and piperazine derivatives as inducers of ldl-receptor expression | SMITHKLINE BEECHAM CORPORATION | 2004-04-22 | — | — | US | disclosed |
| EP-1351936-A1 | ARYL PIPERIDINE AND PIPERAZINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION | GLAXO GROUP LIMITED (GB) | 2003-10-15 | — | — | EP | disclosed |
| WO-2002055496-A1 | ARYL PIPERIDINE AND PIPERAZINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION | GLAXO GROUP LIMITED (GB) | 2002-07-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003851-A1 | SMALL MOLECULE HEMATOPOIETIC GROWTH FACTOR MIMETIC COMPOUNDS THAT ACTIVATE HEMATOPOIETIC GROWTH FACTOR RECEPTORS | MPL, CSF3R, CSF1R | MAOB 4672/4885NR4A2 632/4885RXRA 650/4885 |
| US-20040077654-A1 | Aryl piperidine and piperazine derivatives as inducers of ldl-receptor expression | LDLR, NR1H2, NCOR1 | MAOB 2608/4885NR4A2 147/4885RXRA 139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.